Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cyclacel Pharma (CYCC) Reports Q2 Loss of $1.19
August 10, 2016 4:12 PM EDTCyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($1.19), versus ($1.01) reported last year. Revenue for the quarter came in at $296 thousand, versus $222 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
... More